Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
The Lancet（2021）
摘要
Eli Lilly and Company.
更多查看译文
关键词
insulin glargine,diabetes,cardiovascular risk,open-label,parallel-group
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要